Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 9/20 | 0.48 |
| ▸ | CDK1 | P06493 | 8/20 | 0.47 |
| ▸ | CDK9 | P50750 | 7/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.47 |
| ▸ | CDK7 | P50613 | 8/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.44 |
| ▸ | CCNH | P51946 | 5/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.44 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276459 | 0.89 | CDK2 (0.55) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL12953465 | 0.89 | CDK2 (0.55) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL12953874 | 0.89 | CDK2 (0.55) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL11930872 | 0.89 | CDK2 (0.55) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL14542866 | 0.89 | GSK3B (0.46) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL14545790 | 0.83 | CDK2 (0.55) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL12953834 | 0.83 | CDK2 (0.63) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL13116922 | 0.82 | CDK2 (0.57) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL14043213 | 0.82 | GSK3B (0.48) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL12954279 | 0.81 | GSK3B (0.71) | CDK2CCNA2CCNA1GSK3BCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | CDK2 64/4885CCNA2 1270/4885CCNA1 1142/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | CDK2 64/4885CCNA2 1270/4885CCNA1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.